Angiogenic Biomarkers in Juvenile Idiopathic Arthritis (MAJIC)

Assistance Publique - Hôpitaux de Paris

Status: Enrolling

Conditions: Juvenile Idiopathic Arthritis (JIA)

Treatments: Biological: Joint puncture; Biological: Blood sample

Study type: Observational

Funder types: Other

Identifiers

NCT05534347

APHP220364

2022-A00468-35 (Other Identifier)

Details and patient eligibility

About

The aim of the study is to determine whether serum inflammatory angiogenic markers (eg, semaphorins, CCN1) predict severity of juvenile idiopathic arthritis defined by structural progression and/or therapeutic escalation.

Full description

Juvenile idiopathic arthritis (JIA) is a heterogeneous group of chronic inflammatory rheumatic diseases beginning before the age of 16. The most common pediatric rheumatologic disease. JIA is the most common pediatric rheumatologic disease. Apart from clinical features and the biological inflammatory syndrome, no predictive parameter for the severity of JIA, especially polyarticular JIA, has been identified. The team has been interested in the prognosis of RA for many years. Thus, the investigators have conducted various studies in search of biological parameters associated with the joint prognosis of RA patients, which allowed the investigator to discover the interest of angiogenic and inflammatory biomarkers such as semaphorins and CCN1 protein. This has been demonstrated in vitro but also in vivo from sera of RA patients. These markers are associated with activity and structural damage in RA.

The project aims to study the interest of these same angiogenic biomarkers in the serum of JIA patients in order to establish whether, as in RA, they are also associated with disease severity.

Enrollment: 300 estimated patients

Sex: All

Ages: 16+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Greater than or equal to 16 years-old
• Diagnosis of Juvenile Idiopathic Arthritis with specialized follow up in Rheumatology at Cochin Hospital
• No-opposition to the research
• Patient with health insurance
• Mastery of the French language

Exclusion criteria

• Patient under curatorship or guardianship
• Patient receiving french state medical aid

Trial design

300 participants in 1 patient group

Juvenile Idiopathic Arthritis

Description:

Patients seen in a specialized rheumatology consultation for the management of juvenile idiopathic arthritis in an adult service, after information and collection of their non-opposition.

Treatment:

Biological: Blood sample

Biological: Joint puncture